Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreementPUBT·1 day ago, 04:27 PMKURA-3.76%
Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination DataTip Ranks·Jul 27 at 12:45 PMKURA-3.76%
Kura Oncology Reports 50% Response Rate in RCC Combination StudyMarket Beat·Jul 27 at 11:01 AMKURA-3.76%
Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCCTip Ranks·Jul 27 at 10:55 AMKURA-3.76%
Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinomaPUBT·Jul 27 at 08:26 AMKURA-3.76%
Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trialPUBT·Jul 27 at 05:32 AMKURA-3.76%
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 | KURA Stock NewsStockTitan·Jul 26 at 09:32 PMKURA-3.76%
Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)Tip Ranks·Jul 22 at 04:56 AMKURA-3.76%
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 | KURA Stock NewsStockTitan·Jul 13 at 10:02 PMKURA-3.76%
